 |
 |
 |
 |
|
|
 |
 |
|
 |
|
 |
 |
 |
|
 |
 |
 |
| Lucy
Donaldson |
Jonathan
Morris |
Steve
Harper |
|
|
||
| Lucy Donaldson is Associate Pro-Vice chancellor for Research academy and Career Development at the University of Nottingham, and Professor of Sensory Physiology. Her expertise in acute and chronic pain, and other sensory neuroscience has resulted in the identification of novel mechanisms that are targets for non-opioid analgesics in arthritis, diabetes and other chronic pain conditions. She is a serial entrepreneur, founder of three companies, and Fellow of the Physiological Society and Royal Society of Biology |
Jonathan
Morris is Professor of Chemistry and Pro Vice
Chancellor of Research Training & Entrepreneurship
at the University of New South Wales, Sydney. His
research group focuses on developing new medicinal
chemistry compounds using his expertise in synthetic
organic chemistry. He has particular expertise in
development of small molecules that can selectively
and potently target splicing factor kinases and has
delivered such as compound that has now entered the
clinic for treatment of diabetic macular oedema. |
Steven Harper is a consultant nephrologist at Southmead Hospital and Honorary Professor in the School of Physiology, Pharmacology and neuroscience at the University of Bristol. He has a lifetime of experience of treating patients with kidney disease, diabetes and other complex disorders, and a research career that has spanned academia and biotech. His joint discovery of novel splice variants of VEGF led to the licensing of patents from Bristol into multiple biotech companies, and he was a Founder and is a Director of Exonate Ltd |
 |
 |
|
| Keith
McDonald |
Andy
Chapman |
|
| Keith McDonald is a former senior executive of Lloyd’s Banking Group with many years of corporate finance experience. He acts as a non-executive director and mentor to several companies ranging from recent start-ups in the hospitality sector to an AIM listed software company with market capitalisation of £0.5Bn. He was also instrumental in the $800M sale of Zylo (University of Bristol spin out) to Novo Nordisk in 2018 | Andy Chapman has worked in leading academic institutions in the UK and Spain where his varied research activities have led to several high impact articles and books. He has specific experience in funding acquisition and a previous chemical SME in which he led customer driven research and development. He is currently CEO of Carbometrics Limited. | |
|
|
||
 |
 |
|
| University of
Nottingham Faculty of Medical and Health Sciences |
University of New
South Wales, Sydney NSW 2052 |
|
|
|
|
Contact: info@emendatherapeutics.com